SAM
TVTX icon

Smartleaf Asset Management’s Travere Therapeutics TVTX Stock Holding History

Smartleaf Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.3K Hold
982
– – ﹤0.01% 1448
2026
Q1 		$27.2K Sell
982
-211
-18% -$6.31K ﹤0.01% 1793
2025
Q4 		$45K Buy
1,193
+487
+69% +$15.8K ﹤0.01% 1610
2025
Q3 		$17K Buy
706
+336
+91% +$6.32K ﹤0.01% 1875
2025
Q2 		$5.46K Sell
370
-276
-43% -$4.58K ﹤0.01% 2017
2025
Q1 		$12.7K Buy
646
+176
+37% +$3.57K ﹤0.01% 1833
2024
Q4 		$8.14K Buy
470
+338
+256% +$5.98K ﹤0.01% 2073
2024
Q3 		$1.85K Buy
132
+72
+120% +$750 ﹤0.01% 2498
2024
Q2 		$496 Hold
60
– – ﹤0.01% 2552
2024
Q1 		$460 Buy
+60
New +$506 ﹤0.01% 1755

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smartleaf Asset Management's TVTX Position: Q2 2026 in Review

Smartleaf Asset Management held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 982 shares worth $57.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1448.

Smartleaf Asset Management first reported a position in TVTX in Q1 2024 and has held it in 10 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Smartleaf Asset Management held 982 shares of Travere Therapeutics worth $57.3K as of Q2 2026.
  • Smartleaf Asset Management left its Travere Therapeutics share count unchanged in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1448 holding.
  • Smartleaf Asset Management first reported a position in Travere Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.